Last reviewed · How we verify
NCT05313737
Opt-in vs. Opt-out for Breast Cancer Screening
NA trial testing Automated message in Breast Cancer in 871 participants. Status unknown.
31 August 2022
Quick facts
| Lead sponsor | VA Puget Sound Health Care System |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | screening |
| Enrollment | 871 |
| Start date | 18 April 2022 |
| Primary completion | 31 August 2022 |
| Estimated completion | 31 August 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Automated message
- Opt-out scheduling
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
VA Puget Sound Health Care System
Who can join
Adults 45 to 75, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized controlled trial that will evaluate the effectiveness two different outreach strategies for a population-based breast cancer screening program at the VA Puget Sound among average risk female Veterans who are due for breast cancer screening.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Automated Opt-Out vs Opt-In Patient Outreach Strategies for Breast Cancer Screening: A Randomized Clinical Trial.
Marcotte LM, Deeds S, Wheat C, Gunnink E, et al · · 2023 · cited 10× · PMID 37695621 · DOI 10.1001/jamainternmed.2023.4321
Verify or expand the search:
- PubMed search for NCT05313737
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other VA Puget Sound Health Care System trials
Trials by the same sponsor.
- NCT06363968 — Biomarkers in the Retina for Prognosticating Mental Health Treatments · NA · recruiting
- NCT05755100 — I MOVE!+UP: Piloting an Integrated Weight Management Program for Veterans With PTSD · NA · completed
- NCT05888623 — Computer Assisted Detection of Neoplasia During Colonoscopy Evaluation · completed
- NCT05012007 — Reminder Modality for CRC Screening · NA · completed
- NCT04923646 — Veteran Primers for CRC Screening · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05313737 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by VA Puget Sound Health Care System
- Last refreshed: 6 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05313737.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing